Research & Development

Pipeline

A working R&D page model for Aoxing’s branded health, wellness, dermatology, and clinical-care programs.

Pipeline Facts

Programs in development3
Most advanced programPhase 3
Brand entities7
Therapeutic focus areas2

Pipeline R&D

Pipeline targeting wellness, dermatologic care, and metabolic health

This draft combines a phase-based pipeline chart with expandable trial-style summaries. Use the dropdown to view all entities or focus on one brand family.

Showing all 3 programs

Program status

Pipeline targeting focused therapeutic and wellness areas

Completed
In progress
Upcoming

Program

Indication

Observational

Preclinical

Phase I/II

Phase III

Approved

Vitatherx VTX-101Daily greens powder formula

Metabolic wellness

Observational

Study Overview: VTX-101 Daily Greens Observational Study

Observational daily-greens supplement study concept assessing adult use of a finished dietary supplement powder over a planned 12-week daily routine, with tolerability, adherence, and patient-reported energy, digestion, recovery, and overall wellness outcomes.

Current status: observational daily-greens concept package
Study model: decentralized observational daily-greens supplement protocol
Next milestone: finalize powder formula, daily-use endpoints, and participant-reported outcome framework

NCT Number: NCT00000000

Vitatherx VTX-220Gut-brain support formulation

Metabolic support

Observational

Preclinical

Study Overview: VTX-220 Gut-Brain Support Study

Early formulation and consumer-acceptance work for a microbiome and stress-support supplement concept.

Current status: preclinical observational product research
Study model: decentralized observational protocol for safety, palatability, and repeat-use feedback
Next milestone: controlled-use observational protocol outline

NCT Number: NCT00000000

SPR-ACNE-301Oral spironolactone acne program (505(b)(2))

Dermatologic inflammation

Preclinical

Phase I/II

Phase 3

Study Overview: SPR-ACNE-301 Phase 3 Pivotal Study

Randomized, double-blind, placebo-controlled pivotal study of oral spironolactone (50 mg once daily for weeks 0–4, then 100 mg once daily through week 24) for moderate-to-severe facial acne in adult women, supporting a 505(b)(2) NDA under a fully off-patent reference drug. Co-primary endpoints at week 24 are IGA Success and percent change in inflammatory lesion count.

Current status: pre-IND planning for the Phase 3 pivotal study
Study model: 1:1 randomized, double-blind, placebo-controlled trial in about 150 adult women aged 18–45 across 15–20 US sites, with 24 weeks of treatment and a week-28 safety follow-up
Next milestone: pre-IND briefing book and Type B meeting, plus CMC and CRO partner selection

NCT Number: NCT00000000

Study Overview

Study-style summaries for the active R&D programs. Select a card to focus the pipeline chart on that study.

Therapeutic areas

Focused sample pages

Two sample therapeutic-area pages are linked below as placeholders for deeper education and future content expansion.

01Metabolic WellnessEnergy, nutrition, and healthy routine supportExplore → 02Dermatologic InflammationSkin barrier, sensitivity, and visible irritationExplore →